We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Medix Biochemica Broadens its Capabilities in Diagnostic Base Matrices Through the Acquisition of Bioresource Technology

Medix Biochemica Broadens its Capabilities in Diagnostic Base Matrices Through the Acquisition of Bioresource Technology content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Medix Biochemica has acquired 100 percent of the shares of Bioresource Technology ("BRT") to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix Biochemica will provide its customers with a comprehensive offering of raw materials for their IVD quality control products. The organization and operations of BRT will form a significant part of Medix Biochemica’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biologicals in St. Louis, Missouri. BRT’s operations will stay in Weston, Florida, and BRT’s President Derik Reichenbach and CEO Ron Dilling will remain as strategic advisors following the acquisition.  

Founded in 1984 by Dr. David Reichenbach, BRT is a provider of high-quality base matrices and other critical raw materials to many IVD manufacturers across the world. With a sharp focus on immunoassay, clinical chemistry and molecular diagnostic assay and QC materials, the company manufactures its products in a state of the art, ISO 13485:2016 certified, 26,000 square foot facility in Weston, Florida and employs a highly skilled team of approximately 20 professionals.

"Together, we have the potential to broaden our offering to IVD companies across the globe. There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer," says Steve Ferguson, CEO of Medix Biochemica. 

"We are excited about joining Medix Biochemica", says Derik Reichenbach, President of BRT. "Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica’s global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica".